Mutation-Directed Therapeutics for Neurofibromatosis Type I

Keyphrases

• Antisense Oligonucleotides 33%
• Biotechnology 33%
• Clinical Trials 33%
• Complementary DNA (cDNA) 33%
• CRISPR Activation 33%
• Direct Therapy 66%
• DNA Repair 33%
• Drug Regulatory 33%
• Exon Skipping 33%
• Genetic Disease 66%
• Loss Function 33%
• Nervous System Tumors 33%
• Neurofibromatosis Type 1 (NF-1) 100%
• Neurofibromatosis Type I 100%
• Neurofibromin 66%
• Non-maximum Suppression 33%
• Oligonucleotide Therapeutics 33%
• Potential Power 33%
• RAS Pathway 33%
• Regulatory Bodies 33%
• RNA Repair 33%
• Skeletal Dysplasia 33%
• Skin Spot 33%
• Therapeutic Approaches 33%
• Therapeutic Procedure 33%
• Tumor Suppressor 33%
• Viral Nanoparticles 33%
• Viral Vectors 33%

Medicine and Dentistry

• Antisense Oligonucleotide 33%
• Bone Dysplasia 33%
• Clinical Trial 33%
• Clustered Regularly Interspaced Short Palindromic Repeat 33%
• Complementary DNA 33%
• Diseases 33%
• DNA Repair 33%
• Exon Skipping 33%
• Genetic Disorder 66%
• Hope 33%
• Nanoparticle 33%
• Nervous System Tumor 33%
• Neurofibromatosis Type I 100%
• Ras Signaling 33%
• RNA Repair 33%
• Signal Transduction 33%
• Tumor Suppressor Protein 33%
• Virus Vector 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Antisense Oligonucleotide 33%
• Bone Dysplasia 33%
• Clinical Trial 33%
• Complementary DNA 33%
• Diseases 33%
• Genetic Disorder 66%
• Nanoparticle 33%
• Nervous System Tumor 33%
• Neurofibromatosis Type 1 100%
• Neurofibromin 66%
• Tumor Suppressor Protein 33%
• Viral Vector 33%